The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Epidermal growth factor (EGF) mutants for wound healing and tissue engineering


Stanford Reference:

11-262


Abstract


A team of Stanford engineers have identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF. They were identified using a novel screening platform with a biological read-out. Their improved mitogenic activity could overcome the current challenge of delivering and maintaining sufficient concentrations of EGF at target sites for applications such as cellular/tissue development or treatment of short-term and chronic wounds.



EGF mutant (point mutations shown in red) mapped onto the crystal structure of EGF (blue) bound to EGFR (grey). This mutant enhances cell proliferation compared to native EGF.



Stage of Research
The inventors have engineered the EGF mutants, characterized their biological activity and demonstrated their effects on human fibroblast cells.

Applications


  • Wound healing - therapeutic agents to accelerate the repair of short-term or chronic wounds
  • Tissue engineering - human tissue culture reagent to direct and accelerate growth and development of cells

Advantages


  • Enhanced activity - first-in-class EGF super-agonists
  • Reduced costs - compared to wild type EGF, less EGF mutant protein would be needed to achieve the same level of mitogenic activity
  • Improved efficacy - EGF mutants may be more effective than wild type EGF because delivery and maintenance of sufficient concentrations of EGF at target sites is currently a limiting step to therapeutic uses of EGF

Publications



Related Technologies


  • S06-058: Engineered EGF polypeptides for improved epidermal and epithelial wound healing (details)


Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 4/1/2013
 

Licensing Contact


Ximena Ares, Licensing Associate
650-724-0960 (Direct)
Login to Request Information

[-] Map/Timeline

92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)
93-168 Peptides That Modulate Interaction Between PKC and RACK

more technologies

Related Keywords


therapeutic: proteins   therapeutic: wound healing   chronic wounds   diabetic wounds   EGFR   Epidermal Growth Factor Mutants for Improved Epidermal and Epith   growth factors   regenerative medicine   tissue culture   tissue engineering   tissue regeneration   tissue repair   wound healing   wound repair   11-262   therapeutic: peptides   therapeutic peptide   peptide therapeutics   peptide biotherapeutics   engineered protein fusion   
 

   

  

Also of Interest...
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)
93-168 Peptides That Modulate Interaction Between PKC and RACK

Recently Viewed...
S11-262 Epidermal growth factor (EGF) mutants for wound healing and tissue engineering